Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

Summary

The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.

Timeline

Start

2019-08-26

Primary completion

2021-08-11

Completion

2024-04-30

Outcome

Met primary endpoint

registry analysis (superiority test); Erenumab 70 mg vs Placebo; p = 0.015; Mean Difference (Net) -1.57 (95% CI -2.83 to -0.30); Mixed Models Analysis NCT03867201 ↗

paper At Week 12, the adjusted mean change from baseline in MMD was - 8.2 days for erenumab and - 6.6 days for placebo, with a statistically significant difference for erenumab versus placebo PMID 36404301 ↗

Publications

• Yu S, Kim BK, Wang H, Zhou J, Banerjee P, Lincy J, Reshetnyak E, Li Z, Leclair D, Wang SJ. Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study. J Headache Pain. 2026 Jun 17. doi: 10.1186/s10194-026-02406-y. Online ahead of print.
• Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Wen S, Yin F, Li Z, Su W, Wang SJ. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain. 2022 Nov 21;23(1):146. doi: 10.1186/s10194-022-01514-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erenumab	Monoclonal antibody	70 mg	Subcutaneous

Indications